AllSci News
Denovo secures US patent for ANK3 genetic biomarker in liafensine treatment-resistant depression
Denovo Biopharma (San Diego, USA) received US Patent No. 12,612,261 from the US Patent and Trademark Office (USPTO) for its DGM4 genetic…
Fosun Pharma partners with UAE-based Arcera on licensing, neuroscience collaboration
Arcera Life Sciences, a life sciences company headquartered in Abu Dhabi and established by sovereign investor ADQ, has signed a Memorandum of…
AbbVie secures exclusive option to acquire Kestrel Therapeutics for USD 1.45b for pan-KRAS inhibitor KST-6051
AbbVie has entered into a warrant agreement with Watertown, Massachusetts-based Kestrel Therapeutics, granting AbbVie an exclusive option to acquire the...
Artelo Biosciences partners with ScienceMachine to apply AI technology to FABP5 inhibitor program
Artelo Biosciences (Nasdaq: ARTL) has entered a strategic collaboration with AI platform company ScienceMachine to apply machine learning to its fatty...
Mirum Pharmaceuticals' brelovitug meets primary endpoint in Phase IIb chronic hepatitis delta virus trial
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that brelovitug met its primary endpoint in the Phase IIb portion of the AZURE-1 study in chronic hepatitis...
Erasca's ERAS-0015 shows strong early efficacy in KRAS-mutant solid tumors
Erasca reported preliminary Phase I dose-escalation data for ERAS-0015, its oral pan-RAS molecular glue, in patients with RAS-mutant solid tumors, with...
Novo Nordisk/Prothena’s coramitug TTR antibody gains FDA Fast Track status
Prothena Corporation plc (Nasdaq: PRTA), headquartered in Dublin, announced that Novo Nordisk has received US FDA Fast Track Designation for coramitug (PRX004),…
GSK and Ionis’ bepirovirsen ASO gains FDA breakthrough designation for chronic hepatitis B
GSK (LSE/NYSE: GSK) and its partner Ionis Pharmaceuticals (Nasdaq: IONS), headquartered in Carlsbad, California, announced that the US FDA has accepted for…
Adial’s seeks FDA National Priority Voucher for 5-HT3 antagonist in alcohol use disorder
Adial Pharmaceuticals (Nasdaq: ADIL), a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, announced submission of an application for AD04 to the…
Crinetics’ Palsonify adds EU approval for acromegaly
The European Commission has approved Palsonify (paltusotine) for the treatment of acromegaly in adults, making it the first once-daily oral therapy authorized…
US FDA seeks Tavneos withdrawal, flags ‘untrue statements’ in approval submission
The US FDA’s Center for Drug Evaluation and Research (CDER) has proposed withdrawing market approval of Tavneos (avacopan), a complement C5a receptor…
AstraZeneca’s Breztri Aerosphere picks up US approval for asthma
The US FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for the maintenance treatment of asthma in adults and adolescents aged 12 years…
Eli Lilly and Profluent form USD 2.25b partnership on AI-designed recombinases for genetic meds
Emeryville, California-based Profluent and Indianapolis-based Eli Lilly and Company (NYSE: LLY) have announced a multi-program strategic research collaboration to design and commercialize…
J&J’s Caplyta gets new US indication to prevent relapse in schizophrenia
Johnson & Johnson announced that the US FDA has approved a supplemental New Drug Application (sNDA) for Caplyta (lumateperone) for the prevention…
Remepy, Merck KGaA collaborate on hybrid drugs combined with AI-personalized digital therapeutics
Remepy, a New York-based digital health startup, has entered a hybrid drugs collaboration with Merck KGaA (FRA: MRK.DE; OTC: MKKGY), Darmstadt, Germany, to...
The AllSci Brief
Free, systematic R&D and deal news. Daily.